139 related articles for article (PubMed ID: 17601341)
1. Saliva soluble HLA as a potential marker of response to interferon-beta 1a in multiple sclerosis: a preliminary study.
Minagar A; Adamashvili I; Kelley RE; Gonzalez-Toledo E; McLarty J; Smith SJ
J Neuroinflammation; 2007 Jul; 4():16. PubMed ID: 17601341
[TBL] [Abstract][Full Text] [Related]
2. Beneficial effect of interferon-beta 1b treatment in patients with relapsing-remitting multiple sclerosis is associated with an increase in serum levels of soluble HLA-I molecules during the first 3 months of therapy.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Govoni V; Caniatti L; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2004 Mar; 148(1-2):206-11. PubMed ID: 14975603
[TBL] [Abstract][Full Text] [Related]
3. Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study.
Adamashvili I; Minagar A; Gonzalez-Toledo E; Featherston L; Kelley RE
J Neuroinflammation; 2005 Jun; 2():13. PubMed ID: 15932635
[TBL] [Abstract][Full Text] [Related]
4. Soluble HLA class I and class II molecules in relapsing-remitting multiple sclerosis: acute response to interferon-beta1a treatment and their use as markers of disease activity.
Minagar A; Adamashvilli I; Jaffe SL; Glabus MF; Gonzalez-Toledo E; Kelley RE
Ann N Y Acad Sci; 2005 Jun; 1051():111-20. PubMed ID: 16126950
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.
Khatri B; Barkhof F; Comi G; Hartung HP; Kappos L; Montalban X; Pelletier J; Stites T; Wu S; Holdbrook F; Zhang-Auberson L; Francis G; Cohen JA;
Lancet Neurol; 2011 Jun; 10(6):520-9. PubMed ID: 21571593
[TBL] [Abstract][Full Text] [Related]
6. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
[TBL] [Abstract][Full Text] [Related]
7. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
[TBL] [Abstract][Full Text] [Related]
8. Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings.
Fainardi E; Rizzo R; Melchiorri L; Vaghi L; Castellazzi M; Marzola A; Govoni V; Paolino E; Tola MR; Granieri E; Baricordi OR
J Neuroimmunol; 2003 Sep; 142(1-2):149-58. PubMed ID: 14512174
[TBL] [Abstract][Full Text] [Related]
9. Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study.
Arnold DL; You X; Castrillo-Viguera C
J Neurol; 2017 Aug; 264(8):1728-1734. PubMed ID: 28685353
[TBL] [Abstract][Full Text] [Related]
10. Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Mitsdoerffer M; Schreiner B; Kieseier BC; Neuhaus O; Dichgans J; Hartung HP; Weller M; Wiendl H
J Neuroimmunol; 2005 Feb; 159(1-2):155-64. PubMed ID: 15652415
[TBL] [Abstract][Full Text] [Related]
11. Alemtuzumab versus interferon β-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes.
Coles AJ; Fox E; Vladic A; Gazda SK; Brinar V; Selmaj KW; Bass AD; Wynn DR; Margolin DH; Lake SL; Moran S; Palmer J; Smith MS; Compston DA
Lancet Neurol; 2011 Apr; 10(4):338-48. PubMed ID: 21397567
[TBL] [Abstract][Full Text] [Related]
12. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
[TBL] [Abstract][Full Text] [Related]
13. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
Mikol DD; Barkhof F; Chang P; Coyle PK; Jeffery DR; Schwid SR; Stubinski B; Uitdehaag B;
Lancet Neurol; 2008 Oct; 7(10):903-14. PubMed ID: 18789766
[TBL] [Abstract][Full Text] [Related]
14. Intrathecal synthesis of soluble HLA-G and HLA-I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Castellazzi M; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2006 Feb; 12(1):2-12. PubMed ID: 16459714
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy.
Zivadinov R; Locatelli L; Cookfair D; Srinivasaraghavan B; Bertolotto A; Ukmar M; Bratina A; Maggiore C; Bosco A; Grop A; Catalan M; Zorzon M
Mult Scler; 2007 May; 13(4):490-501. PubMed ID: 17463072
[TBL] [Abstract][Full Text] [Related]
16. Soluble HLA in saliva of patients with autoimmune rheumatic diseases.
Adamashvili I; Pressly T; Gebel H; Milford E; Wolf R; Mancini M; Sittg K; Ghali GE; Hall V; McDonald JC
Rheumatol Int; 2002 Jun; 22(2):71-6. PubMed ID: 12070679
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Soluble Human Leukocyte Antigen-G (sHLA-G) Isoforms and Regulatory T Cells in Relapsing-Remitting Multiple Sclerosis.
Alsahebfosoul F; Zavaran Hosseini A; Salehi R; Etemadifar M; Esmaeil N; Jamshidian A
Iran J Allergy Asthma Immunol; 2015 Jun; 14(3):298-305. PubMed ID: 26546899
[TBL] [Abstract][Full Text] [Related]
18. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis.
Radue EW; Stuart WH; Calabresi PA; Confavreux C; Galetta SL; Rudick RA; Lublin FD; Weinstock-Guttman B; Wynn DR; Fisher E; Papadopoulou A; Lynn F; Panzara MA; Sandrock AW;
J Neurol Sci; 2010 May; 292(1-2):28-35. PubMed ID: 20236661
[TBL] [Abstract][Full Text] [Related]
19. Brain atrophy in relapsing multiple sclerosis: relationship to relapses, EDSS, and treatment with interferon beta-1a.
Rudick RA; Fisher E; Lee JC; Duda JT; Simon J
Mult Scler; 2000 Dec; 6(6):365-72. PubMed ID: 11212130
[TBL] [Abstract][Full Text] [Related]
20. [Open trial of the effectiveness of interferon beta 1a (Avonex) in the treatment of multiple sclerosis in Poland: MRI results].
Siger-Zajdel M; Lewańska M; Zaleski K; Członkowska A; Kwieciński H; Losy J; Podemski R; Stelmasiak Z; Selmaj K
Neurol Neurochir Pol; 2003; 37(6):1185-97. PubMed ID: 15174232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
